Compare PD & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | DRUG |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.9M | 707.1M |
| IPO Year | 2019 | 2020 |
| Metric | PD | DRUG |
|---|---|---|
| Price | $6.58 | $87.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $12.63 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 2.5M | 156.8K |
| Earning Date | 05-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $492,546,000.00 | N/A |
| Revenue This Year | $3.58 | N/A |
| Revenue Next Year | $2.88 | N/A |
| P/E Ratio | $3.61 | ★ N/A |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $5.70 | $23.18 |
| 52 Week High | $17.45 | $123.75 |
| Indicator | PD | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 59.14 |
| Support Level | $5.99 | $72.06 |
| Resistance Level | $6.70 | $91.69 |
| Average True Range (ATR) | 0.41 | 3.99 |
| MACD | 0.10 | 0.07 |
| Stochastic Oscillator | 61.11 | 63.17 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.